Cardio-Oncology and Multi-Imaging Modalities
Journal of Clinical Medicine · 18.06.2025 · 14 (12) · 4353
DOI: 10.3390/jcm14124353 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.06.2025. Verfasst von Christine M Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Early detection and the rise of targeted cancer treatment have led to increased overall survival and decreased mortality among cancer patients. As the cancer survivor population ages, there is an increased risk for cardiovascular disease due to pre-existing comorbidities, deconditioning during therapy, or the natural progression of aging. Furthermore, with emerging oncologic therapies, there is an increased recognition of their potential cardiovascular toxicities. Indeed, heart disease is the leading cause of death in cancer survivors, which may reflect upon both the success of novel oncologic therapies and their potential cardiovascular toxicities. This recognition has driven the development of cardio-oncology, a multi-disciplinary field that involves collaboration between hematologists, oncologists, and cardiologists to screen, prevent, and manage cardiovascular disease in cancer patients and cancer survivors. The field focuses on early cardiovascular detection and prevention for these patients before, during, and after their oncologic treatment. As oncologic therapies evolve and our knowledge of short- and long-term adverse cardiovascular effects grows, it is critical for physicians to identify those at risk for increased morbidity and mortality, while also balancing the importance of their oncologic treatment plan. Multimodality cardiac imaging is the crux of the diagnosis and surveillance of these patients within cardio-oncology, and includes echocardiography, nuclear, computed tomography (CT), and cardiac magnetic resonance (CMR). Cardiac imaging is essential to establish the baseline function and assess various cardiotoxicities, including left ventricular dysfunction, heart failure, atherosclerosis, vascular injury, and arrhythmias. This review will discuss common oncologic therapies and their cardiotoxic profiles, the cardiac multimodality imaging modalities used in cardio-oncology, and the various approaches for the diagnosis and surveillance of this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
- Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
ORCID-Profile: Christine M Park, Felipe Contreras Yametti, Leandro Slipczuk, Aldo L Schenone
Zitieren
APA
Park, C. M., Lerman, B., Contreras Yametti, F., Garcia, M., Slipczuk, L., Schenone, A. L., Zhang, L., & Gongora, C. A. (2025). Cardio-Oncology and Multi-Imaging Modalities. Journal of Clinical Medicine, 14(12), 4353. https://doi.org/10.3390/jcm14124353
Vancouver
Park CM, Lerman B, Contreras Yametti F, Garcia M, Slipczuk L, Schenone AL, et al. Cardio-Oncology and Multi-Imaging Modalities. Journal of Clinical Medicine. 2025;14(12):4353. doi:10.3390/jcm14124353
BibTeX
@article{Park2025,
author = {Park, Christine M and Lerman, Ben and Contreras Yametti, Felipe and Garcia, Mario and Slipczuk, Leandro and Schenone, Aldo L and Zhang, Lili and Gongora, Carlos A},
title = {Cardio-Oncology and Multi-Imaging Modalities},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {12},
pages = {4353},
doi = {10.3390/jcm14124353}
}
EUVIMED